JP2024544012A5 - - Google Patents

Info

Publication number
JP2024544012A5
JP2024544012A5 JP2024533013A JP2024533013A JP2024544012A5 JP 2024544012 A5 JP2024544012 A5 JP 2024544012A5 JP 2024533013 A JP2024533013 A JP 2024533013A JP 2024533013 A JP2024533013 A JP 2024533013A JP 2024544012 A5 JP2024544012 A5 JP 2024544012A5
Authority
JP
Japan
Prior art keywords
gag
approximately
protein
fusion protein
napdnabp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080834 external-priority patent/WO2023102537A2/en
Publication of JP2024544012A publication Critical patent/JP2024544012A/ja
Publication of JP2024544012A5 publication Critical patent/JP2024544012A5/ja
Pending legal-status Critical Current

Links

JP2024533013A 2021-12-03 2022-12-02 核酸プログラマブル融合タンパク質を送達するためのセルフアセンブルウイルス様粒子ならびにその作製方法および使用方法 Pending JP2024544012A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163285995P 2021-12-03 2021-12-03
US63/285,995 2021-12-03
US202263298621P 2022-01-11 2022-01-11
US63/298,621 2022-01-11
PCT/US2022/080834 WO2023102537A2 (en) 2021-12-03 2022-12-02 Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2024544012A JP2024544012A (ja) 2024-11-26
JP2024544012A5 true JP2024544012A5 (enExample) 2025-12-10

Family

ID=85158785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533013A Pending JP2024544012A (ja) 2021-12-03 2022-12-02 核酸プログラマブル融合タンパク質を送達するためのセルフアセンブルウイルス様粒子ならびにその作製方法および使用方法

Country Status (9)

Country Link
US (1) US20250382334A1 (enExample)
EP (1) EP4441073A2 (enExample)
JP (1) JP2024544012A (enExample)
KR (1) KR20240112361A (enExample)
AU (1) AU2022400961A1 (enExample)
CA (1) CA3238778A1 (enExample)
GB (1) GB2630190A (enExample)
IL (1) IL312889A (enExample)
WO (1) WO2023102537A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2025051278A1 (en) * 2023-09-09 2025-03-13 Geneditbio Limited Engineered protein delivery vehicle
WO2025096936A2 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Use of prime editing in correcting mutations in cdkl5
WO2025137543A1 (en) * 2023-12-22 2025-06-26 President And Fellows Of Harvard College Methods for screening for next generation nucleic acid delivery vectors
CN118126137A (zh) * 2024-01-19 2024-06-04 微光基因(苏州)有限公司 用于递送核酸和蛋白质的类病毒样蛋白颗粒及其制备方法
CN118086408A (zh) * 2024-04-25 2024-05-28 华南理工大学 一种可实现靶向肌肉细胞基因编辑的仿病毒颗粒及其制备方法和应用
WO2026024856A2 (en) 2024-07-23 2026-01-29 The Broad Institute, Inc. Compositions and methods for production of double-stranded dna in cells for programmable gene integration
TW202615664A (zh) * 2024-08-02 2026-04-16 香港商正基基因科技有限公司 用於增強遞送的新型工程化蛋白質遞送載體
WO2026106945A2 (en) 2024-11-12 2026-05-21 The Broad Institute, Inc. Engineered prime editing guide rnas and methods of making and using same
CN119162152B (zh) * 2024-11-18 2025-02-25 南京农业大学三亚研究院 一种扩大编辑范围且提高编辑效率的高精准碱基编辑器
WO2026145595A1 (en) * 2024-12-30 2026-07-09 Suzhou Rocrock No.1 Biotechnology Co., Ltd. Nucleic acid delivery systems, compositions, and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
JP2003514564A (ja) 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
DE102010025907A1 (de) 2010-07-02 2012-01-05 Robert Bosch Gmbh Wellenenergiewandler zur Umwandlung von kinetischer Energie in elektrische Energie
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP7059179B2 (ja) * 2015-10-20 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019226953A1 (en) * 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2020102709A1 (en) * 2018-11-16 2020-05-22 The Regents Of The University Of California Compositions and methods for delivering crispr/cas effector polypeptides

Similar Documents

Publication Publication Date Title
JP2024542790A5 (enExample)
Flügel et al. Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes.
Maurer et al. Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus
Simon et al. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes
Mammano et al. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains
Gallaher Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus
Mansky et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
Mulligan et al. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types
JP2004508808A5 (enExample)
Ciminale et al. Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II
Cherepanov et al. High‐level expression of active HIV‐1 integrase from a synthetic gene in human cells
JP2002503477A5 (enExample)
Delassus et al. Genetic organization of gibbon ape leukemia virus
JP2001513643A (ja) レンチウイルスをベースとするベクター及びベクター系
JP2010535495A5 (enExample)
CA2394261A1 (en) Fusion protein delivery system and uses thereof
JP3264281B2 (ja) Hivパッケージング配列を含むベクター、パッケージング不全hivベクター及びその使用
ES2683820T3 (es) Uso de proteínas GAG no de subtipo B para encapsidación lentiviral
WO2025153043A1 (zh) 用于递送核酸和蛋白质的类病毒样蛋白颗粒及其制备方法
US20040091853A1 (en) Viral reporter particles
Nam et al. Identification of a protease gene of human T-cell leukemia virus type I (HTLV-I) and its structural comparison
Bibollet-Ruche et al. Complete genome analysis of one of the earliest SIVcpz Ptt strains from Gabon (SIVcpzGAB2)
WO1999020742A2 (en) A packaging cell line producing siv-pseudotyped mlv
Lee et al. Cooperative effect of gag proteins p12 and capsid during early events of murine leukemia virus replication
Oertle et al. Complementation studies with Rous sarcoma virus gag and gag-pol polyprotein mutants